Dermata Therapeutics, Inc. (DRMA)
$0.89-12.75%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $606,586
- Beta
- 0.66
- P/E (TTM)
- -0.26
- Short % float
- 16.95%
- Days to cover
- 3.6
- SI change
- -29.6%
- 1W
- -19.82%
- 1M
- -25.21%
- vs SPY 1W
- -20.24%
- vs SPY 1M
- -27.27%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 7
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-100.0%
REV YoY-
ROE-166.7%
EPS YoY-
ROA-157.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.26
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B1.30
P/FCF-
EV/EBITDA-0.02
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO2.81
ND/EBITDA-
BETA0.66
Company news
FAQ
- What is LOPJLB’s current signal on DRMA?
- LOPJLB’s latest quantitative signal on Dermata Therapeutics, Inc. (DRMA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is DRMA in?
- Dermata Therapeutics, Inc. (DRMA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Dermata Therapeutics, Inc. (DRMA) do?
- Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated …